<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="527">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757792</url>
  </required_header>
  <id_info>
    <org_study_id>RC1-2-2021</org_study_id>
    <nct_id>NCT04757792</nct_id>
  </id_info>
  <brief_title>Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU</brief_title>
  <official_title>Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective multicenter study to evaluate the data of COVID-19 patients who were admitted&#xD;
      to university hospitals in relation to their recent administration or maintenance on&#xD;
      non-steroidal anti-inflammatory drugs (NSAID) prior to have COVID-19 disease and to analyze&#xD;
      it in relation to outcome of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data contained in hospital registry were collected, categorized into demographic,&#xD;
      previous medical history, the use of NSAID as maintenance therapy or its recent&#xD;
      administration before diagnosis of COVID-19 disease, presenting manifestations, laboratory&#xD;
      and CT findings, applied therapies or interventions. Outcomes will be categorized as survival&#xD;
      and non-survival outcome. Survivors will be subdivided as complete recovery or recovery with&#xD;
      getting new morbidities. Mortality was subdivided as total hospital and ICU mortality. Data&#xD;
      will be statistically analyzed in relation to outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Actual">February 11, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>6 months</time_frame>
    <description>number of patients who were died secondary to COVID-19 disease or its complications</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">475</enrollment>
  <condition>COVID-19 Disease</condition>
  <arm_group>
    <arm_group_label>No NSAID</arm_group_label>
    <description>included patients who did not receive NSAID prior to having COVID-19 disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apsirin</arm_group_label>
    <description>included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <description>included patients who received celecoxib (CEL) prior to having COVID-19 disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miscellaneous</arm_group_label>
    <description>included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>File inquiry</intervention_name>
    <description>Data extraction out of file registry</description>
    <arm_group_label>Apsirin</arm_group_label>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Miscellaneous</arm_group_label>
    <arm_group_label>No NSAID</arm_group_label>
    <other_name>No interventions</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with diagnosis of COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  assured diagnosis of COVID-19 by RT-PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adel Alkholy, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Banha University, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>BanhƒÅ</city>
        <state>Qalubia</state>
        <zip>0013</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Adel F. Alkholy</investigator_full_name>
    <investigator_title>Professor of Medical Biochemistry</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>NSAID</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Mortality</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Protocol data will be available on request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After publishing</ipd_time_frame>
    <ipd_access_criteria>email</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

